恩帕吉菲
达帕格列嗪
心力衰竭
医学
内科学
心脏病学
重症监护医学
糖尿病
2型糖尿病
内分泌学
作者
Katherine L. Modzelewski,Alexandra Pipilas,Nicholas A. Bosch
出处
期刊:JAMA network open
[American Medical Association]
日期:2024-05-02
卷期号:7 (5): e249305-e249305
被引量:16
标识
DOI:10.1001/jamanetworkopen.2024.9305
摘要
Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been shown to have benefits when used in patients with heart failure. The comparative outcomes of SGLT2 inhibitors relative to each other has not been well defined and may impact medication selection.
科研通智能强力驱动
Strongly Powered by AbleSci AI